There have been treatments approved by the US Food and Drug Administration for relapsing-remitting multiple sclerosis (RRMS) for more than 20 years. During this time, the efficacy of newly approved therapies has steadily improved, and we are now seeing that many patients do well with these treatments. Some patients have fared so well with treatments that neurologists have begun to use the term NEDA (no evidence of disease activity) to describe patients with multiple sclerosis (MS) who do not experience relapses, disability progression, or new lesions on magnetic resonance imaging, which is becoming the new goal of MS therapy.1 Particularly for patients with recent-onset RRMS, it is clear that clinicians have a number of options.
Racke MK, Imitola J. Selection of Patients With Multiple Sclerosis to Undergo Autologous Hematopoietic Stem Cell Transplantation. JAMA Neurol. 2017;74(4):392-394. doi:10.1001/jamaneurol.2016.5925